The Efficacy and Safety of Anlotinib Alone and in Combination with Other Drugs in Advanced Lung Cancer: A Retrospective Cohort Study

OBJECTIVE: Lung cancer is a disease associated with high levels of morbidity and mortality, with approximately 2.1 million new cases every year. Anlotinib is a new small-molecule multitarget tyrosine kinase inhibitor independently developed in China that can inhibit the formation of tumor blood vess...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Lei, Zhang, Hui, Xie, Yalin, Su, Ning, Su, Shan, Zhang, Xianlan, Cen, Wenchang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896944/
https://www.ncbi.nlm.nih.gov/pubmed/35251294
http://dx.doi.org/10.1155/2022/1475871

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8896944/
https://www.ncbi.nlm.nih.gov/pubmed/35251294
http://dx.doi.org/10.1155/2022/1475871

Ejemplares similares